©2022 Stanford Medicine
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Not Recruiting
Trial ID: NCT00186537
Purpose
Approximately 1/4 of the US population has insulin resistance and the associated risk factors
such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver
produces and low HDL cholesterol which is the good cholesterol helping to protect against
heart disease. Currently one known treatment for this a medication called fenofibrate,
another medication that can improve insulin resistance is rosiglitazone, a third treatment
known to improve insulin resistance an decrease triglycerides is weight loss. In this study
insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to
HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of
these treatments and results of insulin sensitivity and cardiac risk profiles will be
compared at the end of the study.
Official Title
Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.
Eligibility
Inclusion Criteria:
Insulin Resistant Triglyceride 150 mg/dL or greater or triglyceride HDL-C ratio 3 or
greater BMI 25-35
Exclusion Criteria:
Diabetes Mellitus History of gall stones History of CHF History of CAD Severe
anemia,kidney, or liver disease
Intervention(s):
drug: Rosiglitazone
drug: Fenofibrate
behavioral: Weight Loss
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305